In summary, this study systematically elucidated the core mechanisms through which ELK4 mediated tumor progression, metabolic reprogramming, and immune evasion in C1 NDUFAB1+ subtype, offering crucial theoretical foundations for developing precision therapeutic strategies targeting this subtype. This evidence concerns the gene ELK4 and neoplasm.